BONEX Bonesupport Holding AB (publ)
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Bonesupport Holding (STO: BONEX)
›
Bonesupport Holding (STO: BONEX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 174 employees.
The shares were at 323.80 SEK on 19 November 2026, up 56.0% over 52 weeks. Its 52-week range is 165.00 SEK to 340.20 SEK: the price is 4.8% below the high and 96.2% above the low.
At a market capitalisation of 21.06B SEK, it trades at 79.4 times trailing earnings and 74.1 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a premium of 61% for BONEX.
Bonesupport Holding reports return on equity of 16.4%, an operating margin of 25.5% and revenue up 39.0% year over year.
It holds more cash than debt, a net cash position of 499.89M SEK. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 6 analysts cover the stock; their mean price target of 374.67 SEK is 15.7% above the current price. The next earnings report is expected on 15 February 2027.